158134 Use of pharmacotherapies by substance abuse treatment facilities

Tuesday, November 6, 2007: 9:45 AM

Cathie E. Alderks, PhD , Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Rockville, MD
Significant advances in pharmacotherapies for the treatment of substance use disorders have been made in recent years. The specific pharmacotherapies vary with the substance of abuse. For example, antabuse, naltrexone, or Campral may be used for alcohol disorders, and methadone or buprenorphine may be used with opioid disorders. However, use of pharmacotherapies is not required and is not offered by all substance abuse treatment facilities. This presentation, which will use data from the National Survey of Substance Abuse Treatment Services (N-SSATS), will investigate the prevalence and changes in the numbers and types of substance abuse treatment facilities that use various pharmacotherapies. In addition, the presentation will discuss methods patients and their families can use to locate treatment facilities that use selected pharmacotherapies. The presentation's objective is to highlight the availability of substance abuse treatment services that use pharmacotherapies.

This presentation is part of the session titled Using Population and Facility Data to Understand Emerging Substance Abuse and Mental Health Phenomena: New Findings from SAMHSA's Office of Applied Studies, chaired by Anna Marsh.

Learning Objectives:
1. Identify major pharmacotherapies offered by substance abuse treatment facilities 2. Describe characteristics of types of substance abuse treatment facilities that offer pharmacotherapies 3. Learn how to find substance abuse treatment facilities that offer treatment using selected pharmacotherapies

Keywords: Substance Abuse Treatment, Substance Abuse

Presenting author's disclosure statement:

Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.